Matrizyme Pharma Corporation has developed MZ-004, an innovative therapy to facilitate angioplasty in patients suffering from Chronic Total Occlusions. These 100% complete blockages of an artery represent a significant under-served market due to their complexity and high rate of treatment failure.
Employees: 11-50